Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 24, 2024Open Access

Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

BFBolivia Crocete Aloysia FernandesUniversity of Saint MaryVSVedant ShahSt. Mary's HospitalMAMuhammad Ashar AliAllegheny Health Network

Discussion

Loading...

Member takes

Implication

Meta-analysis demonstrates reduced risk of progression or death with daratumumab in newly diagnosed multiple myeloma, highlighting efficacy regardless of transplant eligibility.

Key Points

  • Daratumumab significantly lowered disease progression and mortality in newly diagnosed multiple myeloma, benefiting both transplant-eligible and ineligible cohorts.
  • Meta-analysis revealed a hazard ratio for progression of 0.44 in transplant-eligible cohorts and 0.47 in transplant-ineligible cohorts with multiple myeloma.
  • Supports incorporating the CD38 monoclonal antibody into initial therapy, as it significantly boosts overall response rate and complete response frequencies.

Cite This Study

Fernandes et al. (2024) studied this question.

synapsesocial.com/papers/68e579c1b6db643587518fc6https://doi.org/10.20944/preprints202409.1922.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials2025 · 2 citations
  2. 2Efficacy and Safety of Daratumumab‐Based Regimens in Multiple Myeloma: A Systematic Review and Meta‐Analysis of Phase III Randomized Controlled Trials2026
  3. 3Clinical Outcomes of Daratumumab-Containing Regimens in Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2026
  4. 4Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma2025
  5. 5Daratumumab enhances the overall response to multiple myeloma therapy as the number of cycles increases2024